Monoclonal Caveolin 1 Expression in the Differential Diagnosis of Malignant Pleural Mesothelioma and Pulmonary Adenocarcinoma: Is it Useful?

  • Zehra BozdagEmail author
  • Ediz Tutar
  • Omer Faruk Dizibuyuk
  • Kemal Bakir
Original Article


In this study we aim to demonstrate the value of monoclonal Caveolin 1 expression in distinguishing between malignant pleural mesothelioma and pulmonary adenocarcinoma. Total of 129 cases, consisting of 68 cases of malignant pleural mesothelioma (51 epitheloid, 12 biphasic, and 5 sarcomatoid type) and 61 cases of pulmonary adenocarcinoma were examined and stained with monoclonal Caveolin-1. Caveolin 1 expression with a membranous and /or cytoplasmic pattern was detected only in 32.35% (n:22/68) of malignant pleural mesothelioma and 6.5% (n:4/61) of pulmonary adenocarcinoma cases. This finding suggests that the choice of poly/monoclonal antibody for Caveolin 1 in the differential diagnosis of malignant pleural mesothelioma and pulmonary adenocarcinoma is important.


Caveolin 1 Mesothelioma Pulmonary adenocarcinoma 


Compliance with Ethical Standards

Conflict of Interest

There is no conflict of interest.


  1. 1.
    Bibby AC, Tsim S, Kanellakis N, Ball H, Talbot DC, Blyth KG et al (2016) Malignant pleural mesothelioma: an update on investigation, diagnosis and treatment. Eur Respir Rev 25:472–486CrossRefGoogle Scholar
  2. 2.
    Christian Geltner C, Errhalt P, Baumgartner B, Ambrosch G, Machan B (2016) Eckmayr J,; Austrian mesothelioma interest group (AMIG). Management of malignant pleural mesothelioma - part 1: epidemiology, diagnosis, and staging : consensus of the Austrian Mesothelioma Interest Group (AMIG). Wien Klin Wochenschr 128(17–18):611–617CrossRefGoogle Scholar
  3. 3.
    Beckett P, Edwards J, Fennell D, Hubbard R, Woolhouse I, Peake MD (2015) Demographics, management and survival of patients with malignant pleural mesothelioma in the National Lung Cancer Audit in England and Wales. Lung Cancer 88:344–348CrossRefGoogle Scholar
  4. 4.
    Betta PG, Magnani C, Bensi T, Trincheri NF, Orecchia S (2012) Immunohistochemistry and molecular diagnostics of pleural malignant mesothelioma. Arch Pathol Lab Med 136:253–261CrossRefGoogle Scholar
  5. 5.
    Creaney J, Robinson BWS, Geltner C, Errhalt P, Baumgartner B, Ambrosch G, Austrian Mesothelioma Interest Group (AMIG) (2017) Malignant Mesothelioma. biomarkers: from discovery to use in clinical practice for diagnosis, monitoring, screening, and treatment. Chest 152:143–149CrossRefGoogle Scholar
  6. 6.
    Su XY, Li GD, Liu WP, Xie B, Jiang YH (2011) Cytological differential diagnosis among adenocarcinoma, epithelial mesothelioma, and reactive mesothelial cells in serous effusions by immunocytochemistry. Diagn Cytopathol 39:900–908CrossRefGoogle Scholar
  7. 7.
    Gueugnon F, Leclercq S, Blanquart C, Sagan C, Cellerin L, Padieu M, Perigaud C, Scherpereel A, Gregoire M (2011) Identification of novel markers for the diagnosis of malignant pleural mesothelioma. Am J Pathol 178:1033–1042CrossRefGoogle Scholar
  8. 8.
    Churg A, Sheffield BS, Galateau-Salle F (2016) New markers for separating benign from malignant Mesothelial proliferations are we there yet? Arch Pathol Lab Med 140:318–321CrossRefGoogle Scholar
  9. 9.
    Fu P, Chen F, Pan Q, Zhao X, Zhao C, Cho WC et al (2017) The different functions and clinical significances of caveolin-1 in human adenocarcinoma and squamous cell carcinoma. Onco Targets Ther 10:819–835CrossRefGoogle Scholar
  10. 10.
    Amatya VJ, Takeshima Y, Kohno H, Kushitani K, Yamada T, Morimoto C, Inai K (2009) Caveolin- 1 is a novel immunohistochemical marker to differentiate epithelioid mesothelioma from lung adenocarcinoma. Histopathology 55:10–19CrossRefGoogle Scholar
  11. 11.
    Astoul P, Roca E, GalateauSallé F, Scherpereel A (2012) Malignant pleural mesothelioma: from the bench to the bedside. Respiration 83:481–493CrossRefGoogle Scholar
  12. 12.
    Husain AN, Colby T, Ordonez NG et al (2012) Guidelines for pathologic diagnosis of malignant mesothelioma. Arch Pathol Lab Med 137Google Scholar
  13. 13.
    Dinu M, Ciurea RN, Stefan M, Georgescu AC (2012) The role of immunohistochemistry in the diagnosis of neoplastic pleural effusions. Rom J Morphol Embryol 53:817–820Google Scholar
  14. 14.
    Panou V, Vyberg M, Weinreich UM, Meristoudis C, Falkmer UG, Røe OD (2015) The established and future biomarkers of malignant pleural mesothelioma. Cancer Treat Rev 41:486–495CrossRefGoogle Scholar
  15. 15.
    Richter G, Heidersdorf H, Hirschfeld D, Krebbel F (2016 Mar 4) Positive TTF-1 expression in malignant mesothelioma: a case report. Am J Case Rep 17:133–136CrossRefGoogle Scholar
  16. 16.
    Chaouche-Mazouni S, Scherpereel A, Zaamoum R, Mihalache A, Amir ZC, Lebaïli N, Delaire B, Gosset P (2015) Claudin 3, 4, and 15 expression in solid tumors of lung adenocarcinoma versus malignant pleural mesothelioma. Ann Diagn Pathol 19(4):193–197CrossRefGoogle Scholar
  17. 17.
    Carbone M, Shimizu D, Napolitano A, Tanji M, Pass HI, Yang H, Pastorino S (2016) Positive nuclear BAP1 immunostaining helps differentiate non-small cell lung carcinomas from malignant mesothelioma. Oncotarget 7:59314–59321CrossRefGoogle Scholar
  18. 18.
    Sahin N, Akatli AN, Celik MR, Ulutas H, Samdanci ET, Colak C (2017) The role of CD90 in the differential diagnosis of pleural malignant mesothelioma, pulmonary carcinoma and comparison with Calretının. Pathol Oncol Res 23:487–491CrossRefGoogle Scholar
  19. 19.
    Üçer Ö, Dağli AF, Kiliçarslan A, Artaş G (2013) Value of Glut-1 and Koc markers in the differential diagnosis of reactive mesothelial hyperplasia, malignant mesothelioma and pulmonary adenocarcinoma. Turk Patoloji Derg 29:94–100Google Scholar
  20. 20.
    Amatya VJ, Kushitani K, Mawas AS, Miyata Y, Okada M, Kishimoto T et al (2017) MUC4, a novel immunohistochemical marker identified by gene expression profiling, differentiates pleural sarcomatoid mesothelioma from lung sarcomatoid carcinoma. Mod Pathol 30:672–681CrossRefGoogle Scholar
  21. 21.
    Ren R, Yin P, Zhang Y, Zhou J, Zhou Y, Xu R et al (2016) Diagnostic value of fibulin-3 for malignant pleural mesothelioma: a systematic review and meta-analysis. Oncotarget 7:84851–84859Google Scholar
  22. 22.
    Jia Y, Wang N, Wang J et al (2014) Down-regulation of stromal caveolin-1 expression in esophageal squamous cell carcinoma: a potent predictor of lymph node metastases, early tumor recurrence, and poor prognosis. Ann Surg Oncol 21:329–336CrossRefGoogle Scholar
  23. 23.
    Zhan P, Shen XK, Qian Q et al (2012) Expression of caveolin-1 is correlated with disease stage and survival in lung adenocarcinomas. Oncol Rep 27:1072–1078CrossRefGoogle Scholar
  24. 24.
    Ma X, Liu L, Nie W, Li Y, Zhang B, Zhang J, Zhou R (2013) Prognostic role of caveolin in breast cancer: a meta-analysis. Breast 22:462–469CrossRefGoogle Scholar
  25. 25.
    Tang Y, Zeng X, He F, Liao Y, Qian N, Toi M (2012) Caveolin-1 is related to invasion, survival, and poor prognosis in hepatocellular cancer. MedOncol 29:977–984Google Scholar
  26. 26.
    Nam KH, Lee BL, Park JH, Kim J, Han N, Lee HE, Kim MA, Lee HS, Kim WH (2013) Caveolin 1 expression correlates with poor prognosis and focal adhesion kinase expression in gastric cancer. Pathobiology 80:87–94CrossRefGoogle Scholar
  27. 27.
    Suzuoki M, Miyamoto M, Kato K, Hiraoka K, Oshikiri T, Nakakubo Y, Fukunaga A, Shichinohe T, Shinohara T, Itoh T, Kondo S, Katoh H (2002) Impact of caveolin-1 expression on prognosis of pancreatic ductal adenocarcinoma. Br J Cancer 87:1140–1144CrossRefGoogle Scholar
  28. 28.
    Zhao Z, Han FH, Yang SB, Hua LX, Wu JH, Zhan WH (2015) Loss of stromal caveolin-1 expression in colorectal cancer predicts poor survival. World J Gastroenterol 21:1140–1147CrossRefGoogle Scholar
  29. 29.
    Joo HJ, Oh DK, Kim YS, Lee KB, Kim SJ (2004) Increased expression of caveolin-1 and microvessel density correlates with metastasis and poor prognosis in clear cell renal cell carcinoma. BJU Int 93:291–296CrossRefGoogle Scholar
  30. 30.
    Karam JA, Lotan Y, Roehrborn CG, Ashfaq R, KarakiewiczPI SSF (2007) Caveolin-1 overexpression is associated with aggressive prostate cancer recurrence. Prostate 67:614–622CrossRefGoogle Scholar
  31. 31.
    von Ruhland CJ, Campbell L, Gumbleton M, Jasani B, Newman GR (2004) Immunolocalization of caveolin-1 in rat and human mesothelium. J Histochem Cytochem 52:1415–1425CrossRefGoogle Scholar
  32. 32.
    Thapa B, Walkiewicz M, Murone C, Asadi K, Deb S, Barnett S, Knight S, Mitchell P, Liew D, Watkins DN, John T (2016) Calretinin but not caveolin-1 correlates with tumour histology and survival in malignant mesothelioma. Pathology 48:660–665CrossRefGoogle Scholar
  33. 33.
    Righi L, Cavallo MC, Gatti G, Monica V, Rapa I, Busso S et al (2014) Tumor/stromal caveolin-1 expression patterns in pleural mesothelioma define a subgroup of the epithelial histotype with poorer prognosis. Am J Clin Pathol 141:816–827CrossRefGoogle Scholar
  34. 34.
    Attanoos RL, Griffin A, Gibbs AR (2003) The use of immunohistochemistry distinguishing reactive from neoplastic mesothelium. A novel use for desmin and comparative evaluation with epithelial membrane antigen, p53, platelet-derived growth factor-receptor, P-glycoprotein and Bcl-2. Histopathology 43:231–238CrossRefGoogle Scholar

Copyright information

© Arányi Lajos Foundation 2019

Authors and Affiliations

  • Zehra Bozdag
    • 1
    Email author
  • Ediz Tutar
    • 1
  • Omer Faruk Dizibuyuk
    • 1
  • Kemal Bakir
    • 1
  1. 1.Department of PathologyGaziantep University, Medical SchoolGaziantepTurkey

Personalised recommendations